The Central Council for Research in Homoeopathy (CCRH), under the Ministry of Ayush, and the ICMR–National Institute of Cancer Prevention and Research (ICMR-NICPR) have signed a Memorandum of Understanding (MoU) to collaborate on a research study titled “Comprehensive Transcriptomic & Epigenomic Assessment of Homeopathic Preparation of Hydrastis & Condurango Homeopathy Drugs in Lung Cancer Cell Lines & Animal Model System.”
The study aims to investigate the molecular mechanisms of homeopathic medicines and evaluate their anticancer effects in vitro and in vivo, focusing on Hydrastis and Condurango preparations.
The MoU was signed by Dr. Subhash Kaushik, Director General of CCRH, and Dr. Shalini Singh, Director of ICMR-NICPR, in the presence of Dr. R. Suresh Kumar, Scientist-F at ICMR-NICPR and Principal Investigator of the study. Also present were key members of the research team, including Dr. K.C. Muralidharan, Assistant Director (H)/Scientist-4, CCRH; Dr. Manas R. Sarangi, Research Officer (H)/Scientist-3, CCRH and co-ordinator of the study; and Dr. Pramod Kumar, Scientist-D, ICMR-NICPR, along with other scientists from ICMR-NICPR.
The signing of the MoU was coordinated by Dr. Manas R. Sarangi, ensuring a seamless collaboration framework for the study, which seeks to provide scientific insights into the potential anticancer properties of homeopathic drugs.
